Georgios Chalikias

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9255490/publications.pdf

Version: 2024-02-01

87	1,827	236925	302126
papers	citations	25 h-index	39 g-index

87	87	87	2966
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pericardial effusion in hypertrophic cardiomyopathy patients: increased right atrial pressure as a common denominator. International Journal of Cardiovascular Imaging, 2022, 38, 339.	1.5	0
2	Renal artery revascularization is a controversial treatment strategy for renal artery stenosis: A case series and a brief review of the current literature. Hellenic Journal of Cardiology, 2022, 65, 42-48.	1.0	1
3	Lack of association of the 11 beta-hydroxysteroid dehydrogenase type 1 gene 25669dupA polymorphism with obesity and metabolic syndrome. Hellenic Journal of Cardiology, 2021, 62, 164-166.	1.0	0
4	Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management. Angiology, 2021, 72, 808-818.	1.8	38
5	Autoimmune reactivity is present in patients with incident coronary artery ectasia. Coronary Artery Disease, 2021, Publish Ahead of Print, 733-735.	0.7	2
6	Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis. TH Open, 2021, 05, e113-e124.	1.4	3
7	Total coronary occlusion in non ST elevation myocardial infarction: Time to change our practice?. International Journal of Cardiology, 2021, 329, 1-8.	1.7	14
8	Non ST-elevation myocardial infarction (NSTEMI) patients with total coronary artery occlusion: More than meets the eye. International Journal of Cardiology, 2021, 333, 52.	1.7	0
9	Echocardiography derived intra-ventricular pressure gradients: a window to the temporal and spatial components of diastolic dysfunction. International Journal of Cardiovascular Imaging, 2021, 37, 2675-2678.	1.5	1
10	Minimally invasive cardiac surgery: in the pursuit to treat more and hurt less. Journal of Thoracic Disease, 2021, 13, 6209-6213.	1.4	0
11	Triggering receptor expressing on myeloid cells (TREM)-1 and acute myocardial infarction: An association vs. causality conundrum. International Journal of Cardiology, 2021, 344, 222-223.	1.7	0
12	Left atrial wall thickness; at the forefront of atrial fibrillation ablation strategies. International Journal of Cardiovascular Imaging, 2021, 37, 3537-3538.	1.5	0
13	Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. Hellenic Journal of Cardiology, 2020, 61, 112-117.	1.0	9
14	Cholesterol content of erythrocyte membranes and elusive target. Thrombosis Research, 2020, 185, 32.	1.7	2
15	Distribution, infrastructure, and expertise of heart failure and cardioâ€oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413.	3.1	6
16	ISCHEMIA trial: Is there enough evidence to drive a change in clinical practice? A critical appraisal. Hellenic Journal of Cardiology, 2020, 61, 204-207.	1.0	2
17	Comparison of novel LDL cholesterol equations in myocardial infarction patients: Clinical impact on risk re-classification and lipid treatment goals on secondary prevention. Atherosclerosis, 2020, 313, 96-101.	0.8	1
18	Letter by Tziakas et al Regarding Article, â€œAortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targetsâ€. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e180-e181.	2.4	0

#	Article	IF	Citations
19	Angiotensin Receptor Neprilysin Inhibitorsâ€"2019 Update. Cardiovascular Drugs and Therapy, 2020, 34, 707-722.	2.6	3
20	Effect of Sacubitril/Valsartan on circulating catecholamine levels during a 6-month follow-up in heart failure patients. Timeo Danaos et dona ferentes?. Acta Cardiologica, 2020, 76, 1-6.	0.9	2
21	Application of 17 Contrast-Induced Acute Kidney Injury Risk Prediction Models. CardioRenal Medicine, 2020, 10, 162-174.	1.9	6
22	Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease. Journal of Clinical Medicine, 2019, 8, 1000.	2.4	12
23	Contrast induced nephropathy an elusive disease entity â€" More questions than answers. International Journal of Cardiology, 2019, 290, 77-78.	1.7	1
24	Lysed Erythrocyte Membranes Promote Vascular Calcification. Circulation, 2019, 139, 2032-2048.	1.6	37
25	Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. International Journal of Cardiology, 2019, 283, 48-54.	1.7	27
26	The Incidence and the Prognostic Impact of Acute Kidney Injury in Acute Myocardial Infarction Patients: Current Preventive Strategies. Cardiovascular Drugs and Therapy, 2018, 32, 81-98.	2.6	26
27	A patient with an extensive coronary artery thrombus. Hellenic Journal of Cardiology, 2018, 59, 347-348.	1.0	2
28	Manual Versus Mechanical Compression of the Radial Artery After TransradialÂCoronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1050-1058.	2.9	32
29	Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PLoS ONE, 2018, 13, e0188695.	2.5	12
30	Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes. European Cardiology Review, 2018, 13, 42.	2.2	28
31	COMPARISON OF CIN RISK PREDICTION MODELS: A PROSPECTIVE COHORT STUDY. Journal of the American College of Cardiology, 2017, 69, 1363.	2.8	0
32	Novel echocardiographic prognostic markers for cardiac tamponade in patients with large malignant pericardial effusions: A paradigm shift from flow to tissue imaging. Echocardiography, 2017, 34, 1315-1323.	0.9	4
33	C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction. BMC Nephrology, 2017, 18, 202.	1.8	8
34	Prevention of Contrast-Induced Acute Kidney Injury: an Update. Cardiovascular Drugs and Therapy, 2016, 30, 515-524.	2.6	40
35	Differences between perivascular adipose tissue surrounding the heart and the internal mammary artery: possible role for the leptin-inflammation-fibrosis-hypoxia axis. Clinical Research in Cardiology, 2016, 105, 887-900.	3.3	48
36	Contrast-Induced Acute Kidney Injury: An Update. Cardiovascular Drugs and Therapy, 2016, 30, 215-228.	2.6	64

#	Article	IF	Citations
37	Biomarkers of the Extracellular Matrix and of Collagen Fragments. , 2016, , 87-124.		3
38	Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction. International Journal of Cardiology, 2015, 197, 48-55.	1.7	21
39	Biomarkers of the extracellular matrix and of collagen fragments. Clinica Chimica Acta, 2015, 443, 39-47.	1.1	37
40	Biomarkers of the Extracellular Matrix and of Collagen Fragments. , 2015, , 1-38.		0
41	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1487-1493.	1.6	39
42	Acute Phase Treatment of Pulmonary Embolism. Current Vascular Pharmacology, 2014, 12, 393-400.	1.7	4
43	Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention. International Journal of Cardiology, 2013, 163, 46-55.	1.7	74
44	Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: Modulatory effects of rosuvastatin. International Journal of Cardiology, 2013, 170, 173-181.	1.7	19
45	Differential Effect of Baseline Adiponectin on All-Cause Mortality in Hemodialysis Patients Depending on Initial Body Mass Index. Long-Term Follow-Up Data of 4.5 Years. , 2013, 23, 45-56.		18
46	Leptin-Dependent and Leptin-Independent Paracrine Effects of Perivascular Adipose Tissue on Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 980-987.	2.4	57
47	Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. European Journal of Preventive Cardiology, 2012, 19, 62-71.	1.8	23
48	Red blood cell distribution width â€“ a strong prognostic marker in cardiovascular disease â€“ is associated with cholesterol content of erythrocyte membrane. Clinical Hemorheology and Microcirculation, 2012, 51, 243-254.	1.7	57
49	Anti-inflammatory Cytokines: A Wolf in Sheep's Clothing?. American Journal of Medicine, 2012, 125, e19.	1.5	0
50	Usefulness of Matrix Metalloproteinase-9 Plasma Levels to Identify Patients With Preserved Left Ventricular Systolic Function After Acute Myocardial Infarction Who Could Benefit from Eplerenone. American Journal of Cardiology, 2012, 110, 1085-1091.	1.6	20
51	Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure. Quality of Life Research, 2012, 21, 143-153.	3.1	12
52	Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease. Acta Pharmacologica Sinica, 2011, 32, 417-424.	6.1	18
53	Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. International Journal of Cardiology, 2011, 150, 22-27.	1.7	26
54	Plasma leptin and adiponectin concentrations in healthy, non-obese children. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 313-8.	0.9	8

#	Article	IF	Citations
55	Significance of the cholesterol content of erythrocyte membranes in atherosclerosis. Clinical Lipidology, 2010, 5, 449-452.	0.4	9
56	Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy. European Journal of Pharmacology, 2010, 628, 164-170.	3.5	8
57	Associations Between Collagen Synthesis and Degradation and Aortic Function in Arterial Hypertension. American Journal of Hypertension, 2010, 23, 488-494.	2.0	41
58	The role of red blood cells in the progression and instability of atherosclerotic plaque. International Journal of Cardiology, 2010, 142, 2-7.	1.7	49
59	Resolution of symptoms and serum peptides of collagen type I turnover in acute heart failure patients. Acta Cardiologica, 2009, 64, 29-33.	0.9	7
60	A rare case of late right ventricular perforation by a passive-fixation permanent pacemaker lead. Europace, 2009, 11, 968-969.	1.7	13
61	Oxidised lowâ€density lipoprotein and arterial function in Î²â€thalassemia major. European Journal of Haematology, 2009, 82, 477-483.	2.2	9
62	Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?. Cardiovascular Drugs and Therapy, 2009, 23, 471-480.	2.6	21
63	Cardiovascular involvement in patients with Î²-thalassemia major without cardiac iron overload. International Journal of Cardiology, 2009, 134, 207-211.	1.7	19
64	Effect of Statins on Collagen Type I Degradation in Patients With Coronary Artery Disease and Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 199-202.	1.6	19
65	Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. European Heart Journal, 2008, 29, 2713-2722.	2.2	36
66	Serum levels of collagen typeâ€Ⅰ degradation markers are associated with vascular stiffness in chronic heart failure patients. European Journal of Heart Failure, 2008, 10, 1181-1185.	7.1	22
67	Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coronary Artery Disease, 2008, 19, 583-590.	0.7	15
68	Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace, 2007, 9, 589-596.	1.7	39
69	Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opinion on Pharmacotherapy, 2007, 8, 2225-2234.	1.8	15
70	Role of apolipoprotein E genotype in coronary artery disease. Future Cardiology, 2007, 3, 537-551.	1.2	1
71	Leukocyte activation after coronary stenting in patients during the subacute phase of a previous ST-elevation myocardial infarction. Coronary Artery Disease, 2007, 18, 105-110.	0.7	5
72	Unilateral pulmonary oedema due to lung re-expansion following pleurocentesis for spontaneous pneumothorax. The role of non-invasive continuous positive airway pressure ventilation. International Journal of Cardiology, 2007, 114, 398-400.	1.7	12

#	Article	IF	Citations
73	Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. International Journal of Cardiology, 2007, 117, 333-339.	1.7	44
74	Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis, 2007, 193, 196-203.	0.8	64
75	Total Cholesterol Content of Erythrocyte Membranes Is Increased in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 49, 2081-2089.	2.8	103
76	Apolipoprotein E Genotype and Circulating Interleukin-10 Levels in Patients With Stable and Unstable Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 2471-2481.	2.8	41
77	Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thrombosis Research, 2006, 118, 221-227.	1.7	13
78	Relation of C-Reactive Protein to the First Onset and the Recurrence Rate in Lone Atrial Fibrillation. American Journal of Cardiology, 2006, 97, 659-661.	1.6	73
79	Epidemiology of the diabetic heart. Coronary Artery Disease, 2005, 16, S3-S10.	0.7	26
80	N-Terminal Proâ€“B-Type Natriuretic Peptide and Matrix Metalloproteinases in Early and Late Left Ventricular Remodeling After Acute Myocardial Infarction. American Journal of Cardiology, 2005, 96, 31-34.	1.6	25
81	Comparison of Levels of Matrix Metalloproteinase-2 and -3 in Patients With Ischemic Cardiomyopathy Versus Nonischemic Cardiomyopathy. American Journal of Cardiology, 2005, 96, 1449-1451.	1.6	32
82	Gelatinases [Matrix Metalloproteinase-2 (MMP-2) and MMP-9] Induce Carotid Plaque Instability But Their Systemic Levels Are Not Predictive of Local Events. Annals of Vascular Surgery, 2005, 19, 529-533.	0.9	21
83	Levosimendan Use Reduces Matrix Metalloproteinase-2 in Patients with Decompensated Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 399-402.	2.6	21
84	Clotting state after cardioversion of atrial fibrillation: a haemostasis index could detect the relationship with the arrhythmia duration. Thrombosis Journal, 2005, 3, 2.	2.1	9
85	Interleukin-18: Interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis, 2005, 182, 135-143.	0.8	50
86	Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. International Journal of Cardiology, 2004, 94, 269-277.	1.7	62
87	Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. International Journal of Cardiology, 2003, 92, 169-175.	1.7	36